Comparable stake leader
Vivo Opportunity Fund Holdings, L.P.
SEC ownership of Regulus Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001505512.
Disclosed value leader
Vivo Opportunity Fund Holdings, L.P.
Comparable rows
2/8
Latest evidence
30 Jun 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Vivo Opportunity Fund Holdings, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 8
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Vivo Opportunity Fund Holdings, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001505512
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Regulus Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Vivo Opportunity Fund Hol...
Disclosed value leader
Vivo Opportunity Fund Hol...
Comparable rows
2/8
Latest evidence
30 Jun 2025
13D/G
3/4/5
Lead comparable stake: 3.9%
6 rows are not safely comparable across share classes.
13D/G row: Vivo Opportunity Fund Holdings, L.P.
Quick read
Vivo Opportunity Fund Holdings, L.P. leads the comparable SEC ownership view at 3.9%.
2 of 8 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Vivo Opportunity Fund Holdings, L.P.'s linked filing trail.
Comparable ownership
Top 2
Vivo Opportunity Fund Holdings, L.P.
3.9%
Point72 Asset Management, L.P.
0.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 8 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
3.9%
|
$9,086,956
2,696,426 shares
|
$0 | 31 Mar 2025 |
| Point72 Asset Management, L.P. |
13D/G
|
0.3%
|
$1,977,487
241,157 shares
|
-$30,197,722 | 30 Jun 2025 |
| Denis Drygin |
3/4/5
Chief Scientific Officer
|
—
class O/S missing
|
$119,060
100,000 shares
|
— | 01 Mar 2022 |
| Joseph P. Hagan |
3/4/5
Chief Executive Officer, Director
|
—
class O/S missing
|
—
1,350,000 shares
|
— | 25 Jun 2025 |
| Preston Klassen |
3/4/5
President & Head of R & D, Director
|
—
class O/S missing
|
—
675,000 shares
|
— | 25 Jun 2025 |
| Crispina Calsada |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
—
562,500 shares
|
— | 25 Jun 2025 |
| Christopher Ray Aker |
3/4/5
Sr. VP & General Counsel
|
—
class O/S missing
|
—
487,500 shares
|
— | 25 Jun 2025 |
| Simos Simeonidis |
3/4/5
Director
|
—
class O/S missing
|
—
90,000 shares
|
— | 09 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Regulus Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
Denis Drygin
Net 12M change
$0
Latest report
25 Jun 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Denis Drygin | Chief Scientific Officer | $119,060 | Mixed | 01 Mar 2022 | ||
| Joseph P. Hagan | Chief Executive Officer, Director | $0 | Mixed | 25 Jun 2025 | ||
| Christopher Ray Aker | Sr. VP & General Counsel | $0 | Mixed | 25 Jun 2025 | ||
| Stelios Papadopoulos | Director | $0 | Mixed | 25 Jun 2025 | ||
| William H. Rastetter | Director | $0 | Mixed | 25 Jun 2025 | ||
| Alice Shih-Hou Huang | Director | $0 | Mixed | 25 Jun 2025 | ||
| Pascale Witz | Director | $0 | Mixed | 25 Jun 2025 | ||
| Preston Klassen | President & Head of R & D, Director | $0 | Mixed | 25 Jun 2025 | ||
| Kathryn J. Collier | Director | $0 | Mixed | 25 Jun 2025 | ||
| Hugh Rosen | Director | $0 | Mixed | 25 Jun 2025 | ||
| Crispina Calsada | Chief Financial Officer | $0 | Mixed | 25 Jun 2025 | ||
| Jason R. Nunn | Director | $0 | Mixed | 25 Jun 2025 | ||
| David Baltimore | Director | $0 | Mixed | 25 Jun 2025 | ||
| Simos Simeonidis | Director | Mixed | 09 Jun 2022 |
Recent insider transactions for Regulus Therapeutics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.